UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

Journal of hematology and oncology, 2016-06, Vol.9 (1), p.51-51, Article 51

2016

Volltextzugriff (PDF)

IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

Blood cancer discovery, 2023-11, Vol.4 (6), p.440-451

2023

Volltextzugriff (PDF)

Elotuzumab for the treatment of multiple myeloma

Journal of hematology and oncology, 2016-07, Vol.9 (1), p.55-55, Article 55

2016

Volltextzugriff (PDF)

B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies

Therapeutic Advances in Hematology, 2021-01, Vol.12, p.2040620721989585-2040620721989585

2021

Volltextzugriff (PDF)

Strategies to Overcome High-Risk Multiple Myeloma

The cancer journal (Sudbury, Mass.), 2021-05, Vol.27 (3), p.201-204

Sanchez, Larysa

2021

Volltextzugriff (PDF)

Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival

Blood advances, 2024-10

2024

Volltextzugriff (PDF)

Temporomandibular Joint Dysfunction Syndrome: A Rare Initial Presentation of Adenocarcinoma of the Lung

Chest, 2015-10, Vol.148 (4), p.577A-577B

2015

Volltextzugriff (PDF)

A Case of a Large Pericardial Teratoma of the Anterior Mediastinum in an Adult

Chest, 2015-10, Vol.148 (4), p.35A-35A

2015

Volltextzugriff (PDF)

Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma

Therapeutic Advances in Hematology, 2021-01, Vol.12, p.2040620720987075

2021

Volltextzugriff (PDF)

Gastric adenocarcinoma: clinicopathologic differences among Hispanics and non-Hispanic whites. A single Institution's experience over 14 years

Annals of gastroenterology, 2016-01, Vol.29 (3), p.325-331

2016

Volltextzugriff (PDF)

Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to date

Seminars in oncology, 2020-04, Vol.47 (2-3), p.155-164

2020

Volltextzugriff (PDF)

No needles needed: All-oral therapy options for relapsed and refractory multiple myeloma

Blood reviews, 2023-01, Vol.57, p.100993-100993, Article 100993

2023

Volltextzugriff (PDF)

NSO-01 The Real World Experience of the Incidence, Assessment, and Management of Oral Adverse Events and Weight Loss With Talquetamab Leading to the Development of an Assessment Tool

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S279-S280

2024

Volltextzugriff (PDF)

NSP-02 Real World Experience of Talquetamab Administration and the Prevalence and Management of Associated Dermatological Toxicities

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S283-S283

2024

Volltextzugriff (PDF)

Durable MRD and Imaging-Negative Remission ≥ 5 Years Post-Therapy Predicts Long-Term Progression-Free Survival in Multiple Myeloma Patients - a Single-Center Observational Study

Blood, 2023-11, Vol.142 (Supplement 1), p.1998-1998

2023

Volltextzugriff (PDF)

Comparative Effectiveness of Lenalidomide/Dexamethasone-Based Triplet Regimens for Treatment of Relapsed and/or Refractory Multiple Myeloma in Subgroups Defined By Cytogenetic Risk

Blood, 2022-11, Vol.140 (Supplement 1), p.4308-4309

2022

Volltextzugriff (PDF)

Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

Blood, 2022-11, Vol.140 (Supplement 1), p.10073-10074

2022

Volltextzugriff (PDF)